Over the last six years, Lupin Biotechnology Group (LBG) has been steering its efforts towards the development of affordable, high quality Biosimilars. LBG has a talent pool of 150 scientists who are developing and working on a product basket of 10 Biosimilars. The product basket under development has an interesting mix of blockbuster microbial and mammalian products, addressing diverse and niche therapeutic indications such as Oncology, Inflammation, Antivirals, Osteoporosis, Rheumatoid Arthritis and Ophthalmics.
Highlights, FY 2014
- Lupin’s first biosimilars foray into Advanced markets was marked by the entry into a JV with Yoshindo Inc. for developing and commercializing biosimilars for Japan
- 5 of Lupin’s biosimilar products are slated to enter the Clinical trial phase this year, having successfully completed pre-clinical studies
- 3 pipeline products preparing to enter pre-clinical phase this financial year
The product development conforms to ICH and biosimilar guidelines issued by the Indian regulatory bodies and is also in tune with the global regulatory landscape. The product development has been supported by innovative and proprietary expression systems, innovative process designs and novel formulations as evidenced through encompassing 15 Indian patent applications, 13 PCT applications, 10 patent applications in regulated markets and 23 publications till date. The JV with Yoshindo would also act as a stepping stone for exploring other regulated markets now.
We are now well positioned to write a new chapter in Lupin’s evolution as a global pharmaceutical Company, where we have not only put all the building blocks together but have built a solid foundation to ink a remarkable tomorrow.